StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for KRRO yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $11.00 | $10.18 | -7.45% | 0.1M |
| 05-18 | $10.28 | $9.97 | -3.02% | 0.1M |
| 05-19 | $9.92 | $9.15 | -7.76% | 0.2M |
| 05-20 | $9.25 | $10.01 | +8.22% | 0.2M |
| 05-21 | $9.91 | $10.97 | +10.70% | 0.2M |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2022 2022-12-31 | Q3 2022 2022-09-30 | Q2 2022 2022-06-30 | Q1 2022 2022-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-59.00M | $-64.81M | $-44.53M | $-23.26M |
Net Income | $-58.03M | $-64.22M | $-44.67M | $-23.39M |
EPS (Diluted) | $-227.42 | $-1.83 | Not available | Not available |
Total Assets | $73.74M | $136.01M | $149.66M | $164.94M |
Total Liabilities | $8.91M | $54.04M | $53.80M | $52.27M |
Cash & Equivalents | $36.33M | $43.85M | $42.37M | $49.83M |
Free Cash Flow OCF − CapEx | $-58.78M | $-42.62M | $-30.84M | $-17.36M |
Shares Outstanding | 268.47K | 35.26M | 34.98M | 34.98M |
KRRO is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.